US Patent

US8674825 — Pharma-informatics system

Method of Use · Assigned to Proteus Digital Health Inc · Expires 2029-04-09 · 3y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a system for detecting the actual physical delivery of a pharmaceutical agent, such as an active agent with an identifier, to a body.

USPTO Abstract

Compositions, systems and methods that allow for the detection of the actual physical delivery of a pharmaceutical agent to a body are provided. Embodiments of the compositions include an identifier and an active agent. The invention finds use in a variety of different applications, including but not limited to, monitoring of therapeutic regimen compliance, tracking the history of pharmaceutical agents, etc.

Drugs covered by this patent

Abilify (aripiprazole) · Generic (originally Otsuka/BMS)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2170`	—	Abilify
`U-2170`	—	Abilify
`U-2170`	—	Abilify
`U-2170`	—	Abilify
`U-2170`	—	Abilify
`U-2170`	—	Abilify

Patent Metadata

Patent number: US8674825
Jurisdiction: US
Classification: Method of Use
Expires: 2029-04-09
Drug substance claim: No
Drug product claim: Yes
Assignee: Proteus Digital Health Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.